| S2229 |
Eltrombopag Olamine
|
Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).
|
-
J Transl Med, 2025, 23(1):69
-
iScience, 2024, 27(10):110862
-
J Mol Cell Biol, 2023, 15(3)mjad017
|
|
| S4502 |
Eltrombopag (SB-497115)
|
Eltrombopag (SB-497115), a member of the biarylhydrazone class, is a nonpeptide agonist of the thrombopoietin receptor (TpoR), used to treat chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).
|
-
BMC Biol, 2025, 23(1):24
-
Hemasphere, 2023, 7(6):e906
-
Am J Cancer Res, 2022, 12(6):2697-2710
|
|
| S6624 |
Avatrombopag
|
Avatrombopag (AKR-501,E5501,YM477) is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation.
|
-
Cell Death Dis, 2024, 15(12):932
|
|
| E1352 |
Butyzamide
|
Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia.
|
|
|
| E4969 |
Avatrombopag hydrochloride
|
Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).
|
|
|
| S6988 |
Lusutrombopag
|
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).
|
|
|